ABCB1 p.Glu255Lys

Predicted by SNAP2: A: D (80%), C: D (80%), D: D (53%), F: D (85%), G: D (85%), H: D (85%), I: D (85%), K: D (91%), L: D (85%), M: D (85%), N: D (80%), P: D (91%), Q: D (75%), R: D (91%), S: D (85%), T: D (85%), V: D (85%), W: D (91%), Y: D (85%),
Predicted by PROVEAN: A: D, C: D, D: N, F: D, G: D, H: D, I: D, K: D, L: D, M: D, N: D, P: D, Q: N, R: D, S: D, T: D, V: D, W: D, Y: D,

[switch to compact view]
Comments [show]
Publications
[hide] Takahashi N, Miura M, Scott SA, Kagaya H, Kameoka Y, Tagawa H, Saitoh H, Fujishima N, Yoshioka T, Hirokawa M, Sawada K
Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia.
J Hum Genet. 2010 Nov;55(11):731-7. Epub 2010 Aug 19., [PMID:20720558]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Koldehoff M, Zakrzewski JL, Beelen DW, Elmaagacli AH
Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells.
Cancer Gene Ther. 2013 Jul;20(7):421-7. doi: 10.1038/cgt.2013.31. Epub 2013 Jun 21., [PMID:23788109]

Abstract [show]
Comments [show]
Sentences [show]